Electrocardiographic Left Ventricular Hypertrophy Regression Induced by an Angiotensin Receptor Blocker‐Based Regimen in Hypertensive Patients With the Metabolic Syndrome: Data From the SARA Study

Authors:
  • VBVivencio Barrios
    Vivencio Barrios
  • ACAlberto Calderón
    Alberto Calderón
  • SBSara Barrios
    Sara Barrios
  • RERocio Echarri
    Rocio Echarri
  • JNJosefa Navarro‐Cid
    Josefa Navarro‐Cid
  • EFElena Ferrer
    Elena Ferrer
  • RFRaúl Fernandez
    Raúl Fernandez

Abstract
The authors assessed the effect of an angiotensin receptor blocker (candesartan)‐based regimen on electrocardiographic left ventricular hypertrophy (ECG‐LVH) in 276 patients with hypertension, including 141 with the metabolic syndrome (MS). Baseline blood pressure (BP) and ECG‐LVH parameters did not differ in patients with and without MS. At the study's end, BP had decreased similarly in both groups. At baseline, 26.1% of patients with MS and 24.7% without MS exhibited ECG‐LVH by Cornell product (CorP) criteria (P=NS); 26.8% and 17.2%, respectively, by Sokolow‐Lyon product (SokP) (P=.01); 11.4%and 11.8% by Cornell voltage (CorV) (P=NS); and 12.4% and 6.5% by Sokolow‐Lyon voltage (SokV) (P=.01). At the study's end, in the MS group, prevalence of ECG‐LVH was reduced to 19.5% from 26.1% (P=.001), to 8.5% from 11.4% (P=.01), and to 24.4% from 26.8%(P=.03) by CorP, CorV, and SokP, respectively. In patients without MS, only the CorP criterion showed a significant decrease in ECG‐LVH prevalence, declining to 20.5% (P=.01). The relative risk reduction of ECG‐LVH was higher in patients with MS according to CorV and SokP criteria (P<.01).